News74

Focus on providing Vidence Consortium Fellows with comprehensive genomic information and point-of-care tools to enhance clinical decision making, improve outcomes for oncology patients

Boca Raton, FL and Raleigh, NC – October 27, 2020 – Vidence, an oncology informatics company, has selected the 2bPrecise™ platform, a precision medicine data delivery solution, to make it easier for its Consortium Fellows to unlock the true power of genomic data at the point of care and facilitate the advancement of precision oncology. Vidence’s proprietary SCIMON™ technology platform will seamlessly integrate with the 2bPrecise cloud-based platform delivering data-driven insights directly into the provider’s workflow to prompt an evidence-based choice of action.

Launched in June 2020 to close an evidence gap in oncology, Vidence partners with Consortium Fellows, a network of hospitals, health systems and clinicians that share a strong commitment and passion for improving the treatment journey for cancer patients. Each Consortium Fellow contributes critical oncology data and benefits from the knowledge and insights provided through the services of the SCIMON™ platform.

“The advancements in the science of genomics and genetics represent an important new area in oncology that has critical utility, if successfully unlocked,” says Percy Van Crocker, Jr., MBA, President and Co-Founder of Vidence. “We are proud to be working with 2bPrecise, a company at the forefront of precision medicine technology, as we equip Consortium Fellows with the means to bring valuable insights into their daily practice of precision medicine and accelerate progress in cancer research and treatment.”

The 2bPrecise platform has been implemented at healthcare organizations across the country, including Cancer Treatment Centers of America (CTCA), which rolled out 2bPrecise’s precision oncology functionality across its five comprehensive cancer care hospitals in 2019. The Vidence and 2bPrecise strategic partnership in oncology represents an expansion of this relationship, with CTCA participating as a Vidence Consortium Fellow.

“All of us here are committed to helping improve cancer care, and are confident that Vidence can accelerate progress,” says Assaf Halevy, CEO and Co-Founder of 2bPrecise. “We’re delighted that our point-of-care precision medicine tools will complement the breadth of value Vidence will deliver to Consortium Fellows and, ultimately, all oncology stakeholders.”

About 2bPrecise
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from electronic health records (EHRs), synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

About Vidence, LLC
Vidence harnesses the power of clinical and genomic data and insights to advance the treatment and outcomes for oncology patients. An oncology informatics company, Vidence provides the world’s leading cancer researchers, innovators and treatment providers with access and contribution to the most comprehensive knowledge base of patient journeys and outcomes. Vidence was established as an independent company in order to expand the impact of data-driven analytics and data stewardship in oncology to a broader network of hospital systems, independent hospitals and clinics. It will be led by its three founders: Percy Van Crocker, Jr., Robert Hauser, PharmD, PhD, and Rachel Schweers, PhD, JD. The founders of the renowned Cancer Treatment Centers of America (CTCA) created Vidence to set a standard in the industry for high-quality data. As Vidence partners with a network of hospital systems, independent hospitals and clinics as Consortium Fellows, CTCA is one of these partners. Visit Vidence.com for more information.

Media Contacts:
Dean Mastrojohn (on behalf of Vidence)
dean.mastrojohn@goodfuse.com
C: (347) 585-5620

Erica Navar (on behalf of 2bPrecise)
enavar@ariamarketing.com
C: (909) 538-9541

Fierce Healthcare honors the precision medicine platform for clinical information management capabilities

Raleigh, NC, Sept. 16, 2020 – Fierce Healthcare released its annual Fierce Innovation Report this week, naming 2bPrecise the industry’s top clinical information management solution. The intent of the awards program, according to Fierce Healthcare, is to “showcase organizations that over the past 12 months have demonstrated innovative solutions that have the greatest potential to save money, engage patients, or revolutionize the industry.”

Cloud-based, the 2bPrecise platform consumes molecular data from labs and clinical information from the EHR, synthesizing them into a clinical-genomic ontology. The resulting precision medicine insights are delivered to providers within their familiar workflow across any EHR. Plus, the solution is built to interact with evolving knowledge sources and care guidelines.

These unique capabilities enable health systems to leverage precision medicine insights in myriad ways – driving efficient workflows for genomics interventions, extracting population analytics, building cohorts for trial recruitment, enabling participation in research studies and more.

2bPrecise was similarly honored with the MedTech Breakthrough award as “Best Overall Genomics Solution” earlier this year, and the company received Microsoft Corp.’s 2020 Health Innovation Award in the category of “Reimagine Healthcare.” Industry Wired magazine further recognized 2bPrecise as one of the Top 8 Precision Medicine Companies in the USA this year.

“We are honored to receive this latest recognition from Fierce Healthcare,” said 2bPrecise CEO Assaf Halevy. “The entire 2bPrecise team is driven to create excellent solutions to support clinical decision making within the provider’s workflow – while simultaneously helping improve outcomes and the patient experience.”

Additional winners announced by Fierce Healthcare include Roche (data analytics/business intelligence), Walgreens (digital/mobile health solutions), XSOLIS (financial/operational) and Centivo (population health management/patient engagement).

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Key enhancements include point-of-care tools enabling oncologists to identify and act upon germline information uncovered during tumor profiling

PITTSBURGH, PA – July 23, 2020 – The latest update to the 2bPrecise precision health platform includes functionality to help oncologists identify genetic factors indicating patient risk for secondary cancers, as well as elevated risks for the patient’s family members.

Testing tumor tissue (somatic data) to assist in precise diagnoses and targeted treatments has been a standard of cancer care for years. However, these somatic results may also contain incidental information about mutations contained within the patient’s genetic profile. Presence of these complex mutations typically indicates a need for patients to undergo germline testing, not only to better understand their own cancer susceptibility but to uncover information about heritable variants that should be shared with biological relatives.

Since its development, the 2bPrecise platform has delivered somatic results into the oncology workflow, supporting clinical decision making to shorten the disease-burden timeline and improve outcomes. With the release of v3.0, 2bPrecise is bringing knowledge and NCCN- and ACMG-guidance into the workflow so oncologists will be able to refer patients to a genetic counselor for additional genomic testing when germline variants are found in the somatic results.

“This has been a genuine clinical challenge up until now,” said Joel Diamond, MD, chief medical officer at 2bPrecise. “Of course, oncologists are aware that germline mutations are contained in somatic results. But there has been no way to easily identify and understand the impact of these variants, consult current clinical guidelines to ascertain next-step recommendations, or close the loop by referring the patient for more testing. The enhancements we’ve made to the 2bPrecise precision oncology capabilities fill a critical gap in effective cancer care.”

An enterprise platform with software and tools spanning the care settings and specialties, 2bPrecise offers functionality and workflows beyond cancer care.  2bPrecise v3.0 introduces a single-click patient summary with a roll-up view of all genomic results available for the individual, minimizing clinical workflow disruption and averting alert fatigue. Deeper pharmacogenomics content and detailed result views enable deeper clinical decision support for providers treating pediatric patients, whose phenotype changes as they age past infancy. In addition, via integration with Allscripts dbMotion Agent Hub, the precision medicine platform now ingests clinical data from community sources, as well as the provider’s native EHR. Plus, 2bPrecise v3.0 adds breadth to its underlying knowledgebase architecture so the platform remains on the leading edge of advances in genomic science and associated clinical guidance.

Development of v3.0 capabilities occurred with direct input from 2bPrecise clients, according to CEO Assaf Halevy. “We are fortunate to work with many of the most innovative and intelligent leaders in health care. They have been generous in their advice and counsel, and candid in their feedback. This has allowed the 2bPrecise team to quickly ramp up new functionality that will help clinicians across all specialties use precision medicine to improve clinical practice and patient outcomes.”

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Read More

Read More

Read More

Read More

Read More

Read More

Read More